Risankizumab in real life: preliminary results of efficacy and safety in psoriasis during a 16-week period

Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials

Kenneth B. Gordon, Bruce Strober, Mark Lebwohl et al. · The Lancet · 2018 · 662 citations

Medicine, Clinical Sciences, Pharmacotherapy +11

Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial

Kristian Reich, Melinda Gooderham, Diamant Thaçi et al. · The Lancet · 2019 · 298 citations

Life Sciences, Clinical Sciences, Immunology +11

IL-12 protects from psoriasiform skin inflammation

Paulina Kulig, Stephanie Musiol, Sandra N. Freiberger et al. · Nature Communications · 2016 · 193 citations · Full text

Life Sciences, Dermatology, Immunology +17

Efficacy of risankizumab in patients with moderate‐to‐severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa‐1 and UltIMMa‐2 studies

Bruce Strober, Alan Menter, C. Leonardi et al. · Journal of the European Academy of Dermatology and Venereology · 2020 · 63 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Efficacy and safety of risankizumab in psoriasis patients who failed <scp>anti‐IL</scp> ‐17, anti‐12/23 and/or anti <scp>IL</scp> ‐23: Preliminary data of a real‐life 16‐week retrospective study

Matteo Megna, Gabriella Fabbrocini, Angelo Ruggiero et al. · Dermatologic Therapy · 2020 · 54 citations

Medicine, Immunology, Pharmacology +16